Wendy Stock, MD

The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.

Orca-T is a “big advance” that must be studied further among patients with acute leukemias and myelodysplastic syndromes.

Whether Orca-T competes with post-transplant cyclophosphamide for GVHD prevention must be studied prospectively, said Wendy Stock, MD.

The FDA approval of Orca-T represents an “important advance” in the world of allogeneic transplant, according to Wendy Stock, MD.

Orca-T may facilitate faster immune reconstitution in patients who undergo allogeneic transplant, according to Wendy Stock, MD.

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.

Hematopoietic Cell Transplantation, edited by Drs. Thomas, Blume, and Forman, is an excellent updated second edition of their comprehensive textbook designed for both practitioners involved in transplantation and those interested in the science of stem-cell transplantation.